Safeguarding Thyroid Function Test Reliability in Viet Nam: Immunoassay Interference, Discordant Results and Confirmatory Testing

DIAGNOSTIC SAFETY & RISK MANAGEMENTMEASUREMENT, LEARNING & IMPROVEMENT

11/6/202625 min read

Safeguarding Thyroid Function Test Reliability in Viet Nam: Immunoassay Interference, Discordant Results and Confirmatory Testing

A patient undergoes thyroid function testing and receives results that appear to suggest an overactive thyroid. Free thyroxine (FT4) is elevated, but thyroid-stimulating hormone (TSH) is not suppressed. The patient feels well and has no obvious symptoms of hyperthyroidism.

The findings are unusual. They may raise concerns about a rare endocrine disorder, a pituitary condition or a problem with the laboratory measurements. Before pursuing extensive investigations, however, another possibility deserves consideration: the apparent hormonal abnormality may not accurately reflect the patient's thyroid function.

Certain interfering antibodies or inherited variations in thyroid hormone-binding proteins can affect immunoassay results. Other substances, including biotin, may produce different misleading biochemical patterns depending on the assay. The analyzer may function normally, internal quality control may remain acceptable and the report may contain no technical warning. Nevertheless, an individual measurement can be inaccurate.

Unrecognized interference can lead to unnecessary investigations, incorrect diagnoses, inappropriate medication or delayed recognition of the patient's actual condition. These consequences become particularly important when a laboratory result that appears technically valid is used to justify a major clinical decision.

Thyroid function tests are among the most frequently requested endocrine investigations. For most patients, modern immunoassays provide clinically useful information without requiring specialized evaluation. However, the reliability of an individual result cannot always be established from the reported numbers alone.

In 2026, the European Thyroid Association (ETA) published its guideline, Interference in Immunoassay Measurements Used in Assessment of Thyroid Function. The guideline provides an updated framework for recognizing potentially misleading measurements, investigating suspected interference and communicating findings that could influence patient care.

For healthcare organizations in Viet Nam, the challenge is to translate these recommendations into practical arrangements that reflect available laboratory capabilities and clinical needs. Clinicians need to recognize when thyroid results do not fit the clinical presentation, while laboratory professionals need suitable methods for determining whether the discrepancy reflects genuine physiology or an analytical limitation.

The objective is not to investigate every abnormal thyroid result for interference. It is to recognize clinically important uncertainty and prevent misleading measurements from becoming unsupported diagnoses.

Why Apparently Valid Thyroid Results Can Be Misleading

Thyroid function is commonly evaluated using TSH and FT4, with free triiodothyronine (FT3) and other thyroid-related measurements used in selected circumstances.

These tests provide information about the interaction between the hypothalamus, pituitary gland and thyroid gland. In many patients, the relationship follows a recognizable physiological pattern. Reduced circulating thyroid hormone concentrations generally stimulate TSH secretion, while increased hormone concentrations usually suppress TSH through negative feedback when the regulatory system is functioning normally.

However, this relationship is not absolute in every clinical situation.

Pregnancy, severe illness, medication exposure, pituitary disorders and other physiological or pathological conditions can alter thyroid hormone concentrations or their interpretation. The timing of testing may also matter, particularly when thyroid function is changing or treatment has recently been initiated or modified.

An unexpected combination of results may therefore reflect genuine disease, a physiological response, analytical interference or several factors operating simultaneously.

Modern laboratories commonly measure thyroid-related analytes using automated immunoassays. These systems offer important advantages in sensitivity, throughput, standardization and turnaround time. Nevertheless, their performance depends on biochemical interactions between the substance being measured and the reagents used by the assay.

Other substances present in a patient's specimen may interfere with these interactions, causing the analytical result to differ from the intended measurement.

Depending on the mechanism and assay design, interference can produce falsely increased, falsely decreased or otherwise misleading concentrations. A technically functioning analyzer cannot necessarily recognize every interfering substance present in an individual specimen.

Consequently, a result that passes routine quality control may still require investigation when it is inconsistent with the patient's symptoms, previous measurements or other laboratory findings.

The distinction is important: a laboratory system may be functioning according to its technical specifications while a particular result fails to represent the patient's physiological condition accurately.

What the 2026 European Thyroid Association Guideline Adds

The 2026 ETA guideline was developed by a multidisciplinary group of endocrinologists and laboratory medicine specialists.

Published online on July 17, 2026, and subsequently appearing in the August issue of the European Thyroid Journal, it addresses interference affecting TSH, thyroid hormones, thyroid autoantibodies and selected other thyroid-related laboratory measurements.

The guideline emphasizes that analytical interference should be considered when thyroid function results are inconsistent with the clinical picture or with one another. However, suspicion of interference is not equivalent to confirmation.

The appropriate response begins with clinical assessment and communication between the requesting clinician and laboratory professionals.

The clinician contributes information about symptoms, examination findings, medication and supplement use, previous laboratory results, relevant medical conditions and family history. The laboratory contributes knowledge of assay design, known interfering substances, method-specific limitations and available investigative techniques.

Neither perspective is always sufficient on its own.

A laboratory may recognize an unusual biochemical pattern without knowing that the patient is taking a supplement capable of affecting the assay. Conversely, a clinician may identify a discrepancy between symptoms and laboratory findings without knowing which analytical methods are susceptible to interference.

Effective communication helps determine whether a result is biologically plausible, which measurement may be unreliable and what additional evidence could resolve the uncertainty.

The guideline also recognizes that some cases require specialist biochemical or genetic investigations beyond the capabilities of a routine medical laboratory. Access to regional or referral laboratory expertise may therefore be necessary.

The clinical consequences of interference are not merely theoretical.

A review by Favresse and colleagues, published in Endocrine Reviews in 2018, examined more than 150 published cases involving thyroid immunoassay interference. At least half of the documented cases were associated with misdiagnosis or inappropriate management, including unnecessary treatment, inappropriate changes to existing medication or additional investigations that would otherwise not have been required.

These findings illustrate the potential consequences of unrecognized interference. However, they were drawn from selected published cases and should not be interpreted as representative estimates of the prevalence of interference or the frequency of patient harm.

They provide no basis for estimating how often clinically significant interference occurs in Vietnamese healthcare facilities.

Their value lies in showing how an apparently small analytical problem can have substantial clinical consequences when the resulting measurement is accepted without appropriate evaluation.

How Thyroid Immunoassay Interference Occurs

The mechanisms of interference depend partly on the design of the analytical method.

TSH is commonly measured using an immunometric method, often described as a sandwich immunoassay. This approach uses antibodies that recognize different regions of the TSH molecule. The analytical signal is generally related to the amount of TSH captured within the reaction system.

Interfering substances may create unintended connections between assay antibodies or prevent normal antibody binding. Depending on the mechanism, the reported TSH concentration may be falsely elevated or falsely decreased.

Free thyroid hormones are commonly measured using competitive immunoassays.

These methods differ from sandwich assays because FT4 and FT3 are relatively small molecules. Their measurement is also complicated by the equilibrium between free hormone and hormone bound to circulating proteins.

Only a small fraction of circulating thyroid hormone is normally unbound.

An assay that alters this equilibrium, or is affected by unusual binding proteins, may generate a value that does not accurately represent the patient's physiological free hormone concentration.

This helps explain why the same interfering substance may affect different thyroid measurements in different ways. It also explains why one analytical platform may produce misleading results while another is less affected.

The susceptibility of an assay depends on its architecture, reagents and technical characteristics. As manufacturers update their methods, susceptibility to particular interferences may also change.

Laboratories therefore need to understand the actual methods they use rather than assume that all thyroid immunoassays behave identically.

There is no single investigative procedure that can reliably identify or exclude every possible mechanism of interference.

Biotin Can Produce a Misleading Hyperthyroid Pattern

Biotin is an important example because it may be present in dietary supplements, products marketed for hair and nail health, and prescribed preparations.

Some laboratory immunoassays use biotin-streptavidin interactions as part of their analytical process. When a patient's blood contains sufficiently high concentrations of biotin, it may disrupt these interactions.

In susceptible sandwich immunoassays, including certain TSH methods, biotin may produce falsely low results. In susceptible competitive assays, including some FT4 and FT3 methods, it may produce falsely elevated results.

The combination can resemble the biochemical pattern of hyperthyroidism even when the patient is not hyperthyroid.

This typical pattern differs from elevated FT4 with nonsuppressed TSH, which may raise suspicion of other interference mechanisms or genuine endocrine disorders.

However, not every assay is affected in the same way.

Some thyroid immunoassays do not use biotin-streptavidin technology, and the concentrations required to cause interference differ between platforms.

The risk depends on the assay design, biotin dose, timing of ingestion, duration of use and factors influencing elimination.

An important practical limitation is that there is no single biotin withdrawal interval appropriate for every patient and every analytical method.

Where interference is suspected, repeating the examination after a suitable interval may help clarify the result. That interval should be determined using the patient's circumstances, the suspected exposure and the laboratory's method-specific information.

Patients taking prescribed biotin or other medically necessary treatments should not discontinue them without appropriate professional guidance.

For healthcare organizations, a useful safeguard is to ensure that medication histories include relevant over-the-counter supplements, not only prescription medicines.

Laboratories should also provide a clear route for clinicians to request advice when biotin interference is suspected.

When necessary, an alternative assay that is not susceptible to the same interference may provide more reliable information.

The objective is to establish an accurate interpretation without creating additional risk through inappropriate medication changes or unnecessary investigations.

Antibody Interference and Macro-TSH

Antibodies present in a patient's blood are another important source of misleading thyroid immunoassay results.

Heterophilic antibodies and human anti-animal antibodies may interact with reagent antibodies used in laboratory examinations.

In certain sandwich assays, they can create unintended connections between capture and detection antibodies, producing falsely elevated results. In other circumstances, they may interfere with normal binding and produce falsely low measurements.

Antibodies directed against reagent components, including streptavidin or ruthenium-associated systems, may also affect particular platforms.

The direction and magnitude of interference depend on the antibody and the assay design.

A related but distinct phenomenon is macro-TSH.

Macro-TSH commonly involves complexes formed between TSH and immunoglobulins. Because these complexes have a relatively high molecular weight, they may remain detectable in certain immunoassays while exhibiting little corresponding biological activity.

The reported TSH concentration may therefore appear markedly elevated even when the patient has no convincing clinical or biochemical evidence of hypothyroidism.

However, elevated TSH with normal FT4 does not automatically indicate macro-TSH.

Genuine subclinical hypothyroidism, medication effects and other clinical circumstances must be considered appropriately.

Macro-TSH becomes particularly relevant when elevated TSH persists despite an otherwise inconsistent clinical picture or when results differ substantially between analytical methods.

The distinction matters because treating falsely elevated TSH as evidence of hypothyroidism may expose a patient to unnecessary thyroid hormone replacement or inappropriate dose escalation.

Nevertheless, identifying macro-TSH does not automatically establish that the patient has no thyroid disorder.

Analytical interference and genuine thyroid disease can coexist. A patient with known interference may subsequently develop hypothyroidism or another thyroid condition.

Clinical assessment and the selection of reliable laboratory measurements therefore remain essential.

Free Thyroid Hormone Measurements Have Their Own Limitations

FT4 and FT3 measurements present additional analytical challenges because their accuracy depends on the equilibrium between free hormone and hormone bound to circulating proteins.

Inherited variations affecting thyroid hormone-binding proteins can alter this relationship or influence the performance of particular immunoassays.

Familial dysalbuminemic hyperthyroxinemia (FDH) is an important example.

In this inherited condition, variants affecting albumin alter thyroid hormone binding. Some routine immunoassays may consequently report elevated FT4 concentrations despite the patient having normal thyroid function.

The patient may have elevated FT4 with a nonsuppressed TSH and few or no symptoms suggesting thyrotoxicosis.

This can raise concerns about rare endocrine disorders when the analytical explanation has not been recognized.

The magnitude of the apparent abnormality varies between laboratory methods.

Variations involving thyroxine-binding globulin or transthyretin may also alter thyroid hormone measurements, although the mechanisms and analytical consequences are not identical.

Thyroid hormone autoantibodies present another potential source of interference. These antibodies may interact with assay components and produce misleading FT4 or FT3 values, particularly in susceptible analytical systems.

The clinical interpretation must therefore consider whether an unexpected measurement reflects genuine hormone physiology, altered binding characteristics or interference affecting the assay.

Family history may be informative when several relatives have similar biochemical patterns without corresponding clinical manifestations.

When an inherited binding protein abnormality is suspected, specialist biochemical evaluation and, where justified, genetic testing may help establish the explanation.

The 2026 ETA guideline recommends offering screening to first-degree relatives when an inherited cause of assay interference has been identified.

This recommendation should be applied according to the specific inherited condition, the circumstances of the individuals involved and applicable professional, consent and legal requirements.

Family investigations should not be introduced routinely for every patient with discordant thyroid results.

Medication Effects and Genuine Physiological Changes Must Be Distinguished From Interference

Medication history is essential when investigating unexpected thyroid function results, but not every medication-related abnormality represents analytical interference.

Some medicines genuinely affect thyroid hormone synthesis, secretion, metabolism or TSH regulation.

Amiodarone, for example, can affect thyroid physiology through several mechanisms. Other treatments may influence TSH secretion or alter circulating thyroid hormone concentrations.

These changes may represent genuine biological effects rather than incorrect laboratory measurements.

By contrast, certain substances may influence the analytical measurement itself.

Heparin provides a useful example.

In some circumstances, heparin exposure increases lipoprotein lipase activity, promoting the generation of free fatty acids after blood collection.

These fatty acids can displace thyroid hormones from their binding proteins and cause an apparent increase in measured FT4.

The effect may occur outside the body during specimen handling or analysis. It is particularly relevant in hospitalized patients, where heparin exposure and other factors affecting thyroid measurements may coexist.

Even specialized methods that physically separate free hormone from protein-bound hormone may be affected when the specimen's binding equilibrium has already been altered.

This illustrates why using a more sophisticated analytical method does not automatically eliminate every source of uncertainty.

Pregnancy and severe systemic illness introduce further interpretive challenges.

Pregnancy alters thyroid hormone-binding protein concentrations and influences the interpretation of thyroid hormone measurements. Serious illness can affect hypothalamic-pituitary-thyroid regulation and thyroid hormone metabolism.

These circumstances are not necessarily laboratory errors.

They require appropriate clinical interpretation and, where relevant, consideration of suitable reference intervals and the patient's physiological state.

A reliable diagnostic approach begins by distinguishing changes genuinely occurring in the patient from abnormalities introduced or amplified by the measurement process.

Discordant Results Should Prompt Review, Not an Automatic Diagnosis

Certain thyroid function patterns warrant closer consideration because they may be difficult to reconcile with ordinary physiology.

Elevated FT4 with nonsuppressed TSH is one example.

Other situations include markedly elevated TSH without corresponding clinical or biochemical evidence of hypothyroidism, unexplained differences between thyroid hormone measurements or substantial changes in reported results following a change in analytical platform.

An unexpected change from previous results may also raise concern, particularly when symptoms and treatment have remained stable.

However, these patterns are not specific to assay interference.

Elevated thyroid hormones with nonsuppressed TSH can occur in genuine disorders such as resistance to thyroid hormone beta or a TSH-secreting pituitary tumor.

Medication effects, nonsteady-state thyroid function and other clinical circumstances may produce similar results.

The 2026 ETA guideline recommends excluding assay interference through appropriate specialist laboratory assessment before proceeding to extensive investigations for rare inherited or pituitary causes of discordant thyroid function.

This can help prevent unnecessary imaging, genetic testing and inappropriate treatment.

However, the recommendation should not be interpreted as justification for delaying necessary clinical care in an unstable or otherwise high-risk patient.

Some individuals may have clinically significant thyroid disease despite minimal symptoms. Others may have genuine thyroid dysfunction and analytical interference simultaneously.

The appropriate response depends on the available evidence and the potential consequences of acting on a misleading result or delaying necessary care.

Confirmatory Testing Should Follow the Suspected Mechanism

When analytical interference is suspected, repeating the original test may seem like the simplest solution.

However, repeating the examination using the same method may reproduce the same misleading result if the interfering substance remains present.

The laboratory may demonstrate excellent repeatability without establishing that the measurement is accurate.

A more informative approach is to select investigations according to the suspected mechanism.

Comparison with an alternative immunoassay platform is often a practical first step.

A method using different antibodies, reagent chemistry or assay architecture may be less susceptible to the same interfering substance.

A substantial difference between platforms can support suspicion of interference, but routine assays may also differ because of calibration, analytical bias, reference interval differences or other technical characteristics.

Disagreement between platforms does not automatically prove interference, and agreement does not exclude every possible interfering mechanism.

For suspected TSH interference, serial dilution studies may help assess whether the specimen behaves as expected when diluted.

Unexpected nonlinearity can raise concern about interference, but not every interferent produces detectable nonlinearity. Nor does a nonlinear result identify the precise cause.

Dilution studies also cannot be applied indiscriminately to free thyroid hormone assays because dilution may alter the equilibrium between free and protein-bound hormone.

The investigation must therefore be appropriate for the analyte and suspected mechanism.

Its purpose is not simply to produce a different number. It is to determine which measurements can be trusted and whether the additional information is sufficient for clinical interpretation.

Investigating Macro-TSH and Antibody-Related Interference

When macro-TSH or antibody interference is suspected, additional laboratory techniques may be useful.

Polyethylene glycol (PEG) precipitation is one commonly used approach.

PEG can precipitate immunoglobulins and certain protein complexes, potentially helping identify macro-TSH.

However, PEG precipitation is not a definitive diagnostic test by itself.

Some TSH immunoreactivity may be lost during precipitation even when macro-TSH is absent. Recovery thresholds may also vary according to the analytical method and specimen characteristics.

The 2026 ETA guideline emphasizes the importance of appropriate interpretation criteria and awareness of these limitations.

A systematic review by Piticchio and colleagues, published in Clinical Endocrinology in 2025, examined PEG precipitation as a method for identifying macro-TSH.

The review included 23 studies involving 4,476 participants and supported PEG precipitation as a useful investigative tool, particularly when the clinical picture strongly suggests macro-TSH.

The investigators found that PEG-precipitable TSH exceeded 75% in the reported macro-TSH cases. However, these findings arose from selected studies and should be interpreted within their methodological limitations.

The review also emphasized the importance of considering PEG findings alongside other available evidence.

A low recovery result should therefore not automatically be treated as confirmed macro-TSH without suitable evaluation.

Heterophilic antibody blocking reagents provide another investigative option.

A substantial change in the reported result after treatment with an appropriate blocking reagent may support the presence of antibody interference.

Nevertheless, effectiveness depends on the nature of the interfering antibody, and failure to demonstrate an effect does not reliably exclude interference.

More specialized methods, including gel filtration chromatography, may help clarify selected cases of suspected macro-TSH.

These procedures require technical expertise and may not be available in routine laboratories.

Their use should depend on the importance of resolving the uncertainty, the available analytical capabilities and whether the result could influence patient management.

Increasingly complex testing should not become an end in itself. The investigation should have a defined clinical purpose.

Confirming Free Thyroid Hormone Measurements

When FT4 or FT3 interference is suspected, an alternative immunoassay may provide useful information.

Two-step immunoassays may be less susceptible than certain one-step methods to interference from some serum components because an intermediate washing step reduces their interaction with the assay.

However, two-step methods are not universally resistant to interference.

Specialized approaches, including equilibrium dialysis or ultrafiltration followed by an appropriate hormone measurement method, may be considered when more reliable assessment is needed.

These methods physically separate free hormone from the protein-bound fraction and can reduce susceptibility to several forms of interference affecting routine assays.

The International Federation of Clinical Chemistry and Laboratory Medicine has developed reference measurement procedures for FT4 involving equilibrium dialysis and isotope dilution liquid chromatography-tandem mass spectrometry.

These approaches can support more accurate measurement under appropriately controlled conditions.

However, they require specialized equipment, validated procedures and experienced personnel. They are not routinely available in every medical laboratory.

They are also not completely immune to analytical uncertainty.

Temperature, pH, specimen handling and changes in protein-binding equilibrium can influence specialized measurements.

In selected circumstances, total T4 or total T3 measurements may contribute to the investigation, provided that the effects of binding protein concentrations and characteristics are understood.

The appropriate combination of tests depends on the suspected mechanism and clinical question.

If FT4 or FT3 interference is confirmed and TSH measurement remains reliable, clinical assessment together with TSH may provide a useful basis for evaluating thyroid status. Conversely, when TSH is affected by interference, interpretation may depend more heavily on clinical findings and reliable FT4 or FT3 measurements.

A reliable confirmatory investigation should help determine whether the apparent hormonal abnormality reflects the patient's physiological state rather than merely replacing one uncertain result with another.

Related Thyroid Immunoassays Also Require Appropriate Interpretation

Although TSH, FT4 and FT3 are central to thyroid function assessment, other immunoassays are used to investigate thyroid disorders or monitor selected patients.

These include thyroid peroxidase antibodies, thyroglobulin antibodies, TSH receptor antibodies, thyroglobulin and calcitonin.

They serve different clinical purposes and should not all be described as direct measures of thyroid function.

Nevertheless, some are vulnerable to analytical interference.

For example, thyroglobulin antibodies may interfere with thyroglobulin measurement, which is particularly relevant to follow-up in selected patients with differentiated thyroid cancer.

Depending on the assay and interference mechanism, the reported thyroglobulin concentration may be misleadingly low or elevated.

Another potential problem is the high-dose hook effect in certain immunometric assays.

When the concentration of an analyte is extremely high, the analytical signal may paradoxically become lower than expected.

The 2026 ETA guideline highlights this possibility for thyroglobulin and calcitonin in relevant thyroid cancer settings.

Rare interference affecting TSH receptor antibody assays may also complicate the investigation of suspected Graves' disease.

These examples demonstrate that immunoassay interference extends beyond routine thyroid function measurements.

However, the appropriate investigative method differs according to the biomarker and assay design.

A procedure suitable for suspected TSH interference should not automatically be applied to thyroglobulin, calcitonin or thyroid antibody testing.

Why Routine Quality Control May Not Detect Patient-Specific Interference

An important characteristic of immunoassay interference is that it may occur despite satisfactory routine laboratory quality control.

Internal quality control materials are designed to monitor analytical performance under defined conditions.

They can help identify calibration problems, reagent instability, equipment malfunction and certain other analytical issues.

However, these materials do not necessarily contain the patient-specific antibodies, abnormal binding proteins or medications responsible for an individual interference event.

The quality control result may therefore be acceptable while a particular patient's specimen produces a misleading measurement.

External quality assessment also contributes to laboratory reliability, but participation in an external program does not establish that every possible patient-specific interferent will be detected.

This is why routine quality control should be complemented by clinical and analytical review.

CLSI EP07, Interference Testing in Clinical Chemistry, provides an established framework for evaluating the effects of interfering substances on laboratory measurement procedures.

Its third edition, published in April 2018 and reaffirmed in October 2022, describes approaches for assessing potential interferents, verifying interference claims and investigating unexpected results.

A supplementary practical guide was published on March 17, 2026. CLSI EP37 provides additional information about concentrations of potential interfering substances used in analytical evaluation.

These resources support systematic interference investigation but do not replace the specialized clinical guidance needed for individual thyroid hormone and antibody assays.

The absence of an analyzer warning should therefore not be interpreted as evidence that interference is impossible.

Some clinically consequential problems become apparent only when laboratory results are compared with the patient's symptoms, previous examinations or measurements obtained by another method.

Communicating Confirmed Interference to Support Future Care

Identifying analytical interference is only part of the solution.

If the finding is not communicated and documented appropriately, the patient may encounter the same problem during future healthcare visits.

A misleading thyroid result may be repeated at another laboratory using a similarly susceptible analytical method.

Without knowledge of the previous investigation, clinicians may once again consider unnecessary imaging, medication changes or specialized endocrine testing.

The 2026 ETA guideline addresses this concern directly.

When assay interference is identified, it recommends formal written communication to the relevant referring and primary care physicians. The patient should also receive understandable information about the finding.

This communication can help prevent repeated diagnostic uncertainty.

A useful laboratory report or interpretive comment should identify the affected measurement or method, summarize the investigation performed and explain the implications for future thyroid assessment.

If an alternative assay or measurement approach provides more reliable results, that information may also be valuable.

However, a previous finding of interference should not be treated as proof that every future thyroid result will be unreliable.

Assays may change over time, and the patient's clinical condition may evolve.

A person with previously confirmed interference can subsequently develop genuine thyroid disease.

Documentation should therefore inform future professional judgment rather than permanently exclude the patient from ordinary thyroid assessment.

Healthcare organizations should consider how confirmed interference is recorded in the laboratory information system and medical record.

Where an issued result has been shown to be misleading, the organization should assess whether an amended report, interpretive comment or formal clarification is necessary under its established reporting procedures.

The original report and subsequent investigation should remain appropriately traceable. Silently replacing or deleting earlier results may create additional problems for clinical review and accountability.

Measuring the Reliability of Interference Investigations

Healthcare organizations may find it difficult to determine how frequently clinically important thyroid immunoassay interference occurs.

Some cases may remain unrecognized, while others are investigated only after repeated testing or an unexpected clinical finding.

The proportion of confirmed cases therefore depends partly on the organization's ability to recognize and investigate suspicious results.

A higher detection rate does not necessarily indicate poorer laboratory performance, and a lower detection rate does not automatically demonstrate safer testing.

Measurement should focus on whether suspected interference is handled appropriately.

One useful indicator is the proportion of predefined discordant thyroid function results that receive documented clinical and laboratory review.

The denominator should reflect clearly established criteria rather than include every abnormal thyroid result.

For example, a healthcare organization may identify selected biochemical patterns that warrant further assessment based on its clinical services, assay characteristics and patient population.

Another useful measure is the interval between recognition of a potentially misleading result and availability of an appropriate interpretive conclusion.

The urgency should reflect the clinical circumstances.

An unresolved result that could influence an imminent major treatment decision may require faster clarification than a longstanding discrepancy in a clinically stable patient.

Organizations may also review whether confirmed interference cases are documented appropriately and communicated to the responsible clinical team.

Where an amended report is necessary, its completion and communication may provide another useful measure.

When specialist investigations are referred externally, healthcare organizations may assess whether indicated testing was completed and whether unresolved cases received appropriate professional review.

However, the number of confirmatory tests performed should not be considered a measure of success by itself.

Unnecessary testing may increase costs, delay care and create additional uncertainty.

The more meaningful question is whether the investigation sufficiently clarified the findings to support appropriate patient management.

Selected case reviews may also identify whether unrecognized interference contributed to unnecessary investigations, medication changes or delayed care.

Such conclusions require careful professional assessment and should not be inferred automatically from disagreement between analytical methods.

Building an Effective Clinical-Laboratory Review Process

A reliable response to discordant thyroid function results requires a defined communication pathway between clinicians and laboratory professionals.

The process should allow clinicians to raise concerns about unexpected results and obtain appropriate laboratory advice.

It should also allow laboratory professionals to recognize suspicious patterns and contact requesting clinicians when additional clinical information is needed.

The initial assessment may be relatively straightforward.

Reviewing previous results, symptoms, medication and supplement use, relevant physiological circumstances and the assays used may identify a plausible explanation.

When necessary, the laboratory may arrange testing on an alternative platform or refer a specimen for specialized investigation.

The organization should establish who coordinates the assessment, how findings are documented and who communicates the conclusion.

These responsibilities become particularly important when testing is performed by an external laboratory.

The referring organization should understand which specialist methods are available, what their limitations are and how the resulting interpretation will be incorporated into the patient's clinical record.

A formal referral arrangement may be more realistic than expecting every healthcare facility to establish advanced endocrine testing capabilities.

The 2026 ETA guideline recognizes differences in available resources and recommends access to specialized laboratory and clinical expertise where feasible.

For healthcare organizations with limited analytical capabilities, the most practical improvement may therefore be establishing a reliable route to specialist advice rather than purchasing additional equipment.

The effectiveness of the process should be evaluated through actual cases.

If clinicians continue to encounter repeated uncertainty because laboratory advice is unavailable or important findings are not documented, a written procedure alone has not resolved the problem.

Applying International Guidance in Viet Nam

Thyroid function tests are performed across a broad range of healthcare settings in Viet Nam, including hospitals, specialist clinics and medical laboratories.

The availability of immunoassay platforms and specialized laboratory techniques may differ between facilities.

Some laboratories have access to several analytical systems, while others rely on a single platform.

Specialized procedures such as equilibrium dialysis, gel filtration chromatography or advanced antibody interference investigations may require referral to another laboratory.

These differences should be considered when translating international recommendations into local practice.

The 2026 ETA guideline provides an evidence-informed clinical framework for recognizing discordant thyroid results, selecting proportionate investigations and communicating confirmed interference.

CLSI EP07 provides complementary technical guidance for evaluating analytical interference.

Neither document automatically becomes a statutory requirement for every medical laboratory in Viet Nam.

The national legal framework includes the Law on Medical Examination and Treatment No. 15/2023/QH15, effective January 1, 2024, and Decree No. 96/2023/ND-CP, together with applicable amendments and implementing provisions.

Healthcare organizations must provide services within their authorized professional scope and meet relevant technical and professional requirements.

Laboratory quality management is addressed by Circular No. 01/2013/TT-BYT, as amended by subsequent instruments, including Circular No. 25/2026/TT-BYT.

The amendment affecting Circular No. 01/2013/TT-BYT took effect on August 15, 2026, and concerns participation in external quality assessment arrangements.

It should not be interpreted as establishing a nationwide obligation to perform every specialized interference investigation described in the ETA guideline.

TCVN ISO 15189:2025, Medical Laboratories: Requirements for Quality and Competence, is identical to ISO 15189:2022 and replaces TCVN ISO 15189:2014.

The national standard provides a relevant framework for laboratory competence, quality management, examination processes, reporting and management of risks affecting patients.

It may support laboratories developing procedures for investigating unexpected results and ensuring the validity of examinations.

However, publication of the national standard does not automatically establish a legal obligation for every medical laboratory to obtain ISO 15189 accreditation.

The requirements applicable to an individual facility depend on relevant legislation, authorized activities and applicable accreditation or contractual commitments.

A proportionate approach in Viet Nam may begin with ensuring that clinicians and laboratory professionals understand when thyroid results warrant additional review.

The next priority is to establish practical access to confirmatory testing or specialist interpretation when clinically indicated.

The objective should not be to establish a comprehensive specialist endocrine laboratory in every healthcare facility.

It should be to ensure that clinically important analytical uncertainty can be recognized, investigated and communicated before it leads to avoidable harm.

Protecting Patient Information and Supporting Continuity of Care

Confirmed assay interference may remain relevant beyond the immediate clinical encounter.

Information about affected analytical methods, previous findings and recommended approaches to future testing may need to accompany the patient between healthcare services.

This requires appropriate documentation and protection of personal health information.

Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.

Healthcare organizations processing identifiable laboratory and clinical information should assess the applicable requirements concerning lawful processing, confidentiality, authorized access, information security, retention and disclosure.

Where specimens or results are transferred to referral laboratories, the parties should establish appropriate arrangements concerning specimen handling, confidentiality, technical assessment and reporting.

Patient communication also deserves attention.

An explanation of analytical interference should not unnecessarily alarm the patient or suggest that laboratory testing is generally unreliable.

It should clarify that a particular measurement may have been affected by a recognized analytical limitation and that qualified professionals have identified an appropriate way to interpret or reassess the finding.

When interference has been confirmed, accessible written information may help the patient communicate the issue during future healthcare encounters.

The goal is to reduce repeated diagnostic uncertainty while maintaining confidence in appropriately performed laboratory medicine.

Turning Unexpected Results Into Practical Improvement

Consider a healthcare organization where several clinicians report unexpectedly elevated FT4 measurements with nonsuppressed TSH.

The initial concern may be that the patients have unusual endocrine disorders.

However, a structured review identifies that the results were generated using the same analytical platform and that some patients have plausible sources of assay interference.

The organization may then compare selected specimens using methods with different susceptibility characteristics and determine whether the findings support method-specific interference.

If interference is confirmed, the laboratory can document the affected assays, communicate the findings and assess whether previously issued reports require clarification.

The investigation may also identify opportunities to improve medication history collection, laboratory comments or communication between clinical and laboratory services.

A different situation may involve a patient with persistently elevated TSH, normal FT4 and no convincing clinical evidence of hypothyroidism.

Further investigation may identify macro-TSH.

In that case, the most useful improvement may be ensuring that the finding is clearly documented and that future clinicians understand which thyroid measurements remain reliable.

These examples illustrate why improvement activities should address the causes and consequences of analytical discrepancies rather than apply the same solution to every abnormal result.

Some situations require technical evaluation of an analytical method. Others require more complete clinical information, referral to specialist expertise or better documentation.

A dependable quality management process should recognize these differences and evaluate whether corrective actions have reduced repeated uncertainty.

Strengthening Thyroid Test Reliability as Part of Diagnostic Excellence

Thyroid immunoassays are essential tools in clinical care, and most measurements can be interpreted without extensive additional investigations.

Nevertheless, analytical interference remains an important diagnostic safety concern because a misleading result may appear precise, reproducible and technically acceptable.

Without appropriate clinical and laboratory review, that result may become the basis for an unsupported diagnosis, unnecessary investigations or inappropriate treatment.

The 2026 ETA guideline provides an updated framework for recognizing suspicious findings, coordinating clinical and laboratory assessment, selecting suitable confirmatory methods and communicating confirmed interference.

CLSI EP07 contributes complementary principles for evaluating analytical interference systematically.

For healthcare organizations in Viet Nam, the opportunity is to establish practical arrangements that reflect local laboratory capabilities while preserving appropriate professional responsibilities.

Reliable thyroid function testing does not require treating every unexpected result as an analytical error.

It requires recognizing when laboratory findings are inconsistent with the available clinical evidence, understanding how the analytical method may be affected and having a dependable process for resolving uncertainty that could influence patient care.

The quality of a laboratory service should therefore not be judged solely by turnaround time, analytical precision or satisfactory internal quality control.

It should also be demonstrated by the ability to recognize when a result may be misleading, investigate the concern appropriately and communicate the limitations of the available evidence.

Diagnostic excellence in thyroid function testing depends not only on producing precise laboratory results, but also on recognizing when those results may not reflect the patient's physiological condition and ensuring that clinically important uncertainty is investigated and communicated responsibly.

Selected References and Regulatory Sources

Campi I, Feldt-Rasmussen U, Gruson D, Halsall D, Raverot V, van den Berg S, Moran C. 2026 ETA Guideline on Interference in Immunoassay Measurements Used in Assessment of Thyroid Function. European Thyroid Journal. 2026;15(4). Published online July 17, 2026. DOI: 10.1530/ETJ-26-0011.

Favresse J, Burlacu MC, Maiter D, Gruson D. Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm. Endocrine Reviews. 2018;39(5):830–850. DOI: 10.1210/er.2018-00119.

Moran C, Schoenmakers N, Halsall D, et al. Approach to the Patient With Raised Thyroid Hormones and Nonsuppressed TSH. Journal of Clinical Endocrinology & Metabolism. 2024;109(4):1094–1108. DOI: 10.1210/clinem/dgad681.

Van Uytfanghe K, Ehrenkranz J, Halsall D, et al. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status. Thyroid. 2023;33(9):1013–1028. DOI: 10.1089/thy.2023.0169.

Piticchio T, Chiardi I, Tumminia A, et al. PEG Precipitation to Detect Macro-TSH in Clinical Practice: A Systematic Review. Clinical Endocrinology. 2025;102(3):235–244. Published online December 19, 2024. DOI: 10.1111/cen.15179.

Clinical and Laboratory Standards Institute. CLSI EP07: Interference Testing in Clinical Chemistry. Third edition. April 30, 2018. Reaffirmed October 2022. Accompanied by the CLSI EP07 Guide, published March 17, 2026.

Clinical and Laboratory Standards Institute. CLSI EP37: Supplemental Tables for Interference Testing in Clinical Chemistry.

International Organization for Standardization. ISO 15189:2022: Medical Laboratories — Requirements for Quality and Competence.

Viet Nam National Standard. TCVN ISO 15189:2025: Medical Laboratories — Requirements for Quality and Competence. Identical to ISO 15189:2022, replacing TCVN ISO 15189:2014.

National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. Effective January 1, 2024, as amended.

Government of Viet Nam. Decree No. 96/2023/ND-CP, Detailing Certain Articles of the Law on Medical Examination and Treatment. December 30, 2023, as amended where applicable.

Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, Guiding the Implementation of Laboratory Quality Management at Medical Examination and Treatment Facilities. January 11, 2013, as amended.

Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, Amending and Supplementing Certain Provisions of Circular No. 01/2013/TT-BYT, Circular No. 32/2023/TT-BYT, Circular No. 23/2024/TT-BYT and Circular No. 42/2025/TT-BYT. June 30, 2026. Amendment relevant to laboratory quality management effective August 15, 2026.

National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.

Government of Viet Nam. Decree No. 356/2025/ND-CP, Detailing Certain Provisions and Measures for Implementing the Law on Personal Data Protection. Effective January 1, 2026.

Professional Scope and Disclaimer

This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement and quality improvement.

The content is intended for general professional education and discussion. It does not constitute patient-specific medical advice, a clinical or laboratory diagnosis, an individualized recommendation concerning thyroid testing, interference investigations, confirmatory methods, medication changes or treatment, a determination of professional or technical error, an accreditation assessment or legal advice.

The discussion primarily addresses TSH, FT4, FT3 and selected related thyroid immunoassays. Specialized endocrine disorders, neonatal screening, thyroid cancer surveillance and other clinical circumstances may require additional professional and technical considerations.

An unexpected or discordant thyroid result does not necessarily establish analytical interference. Genuine endocrine disease, physiological changes, medication effects and analytical limitations must be evaluated according to the patient's clinical circumstances.

Confirmatory methods should be selected and interpreted by appropriately qualified and authorized professionals. Their availability and analytical characteristics may differ between laboratories.

Patients should not discontinue prescribed medicines or medically necessary supplements solely because analytical interference is suspected without appropriate professional advice.

References to the European Thyroid Association, CLSI, ISO and other professional guidance do not imply endorsement of this publication by those organizations or establish that their recommendations are automatically mandatory under Vietnamese law.

The applicability of technical standards, professional guidance and Vietnamese legal requirements depends on the healthcare organization's authorized professional activities, licensing arrangements, applicable regulations and any relevant accreditation or contractual commitments.

Decisions concerning thyroid examination procedures, laboratory interpretation, confirmatory investigations, clinical assessment and patient management must remain the responsibility of appropriately qualified healthcare professionals in accordance with applicable Vietnamese law, relevant professional standards and the patient's clinical circumstances.

Diagnostic Excellence Vietnam does not provide thyroid testing, individualized clinical diagnosis, treatment or certification of laboratory services through this educational publication.